Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study
- 26 January 2011
- Vol. 60 (8), 1109-1116
- https://doi.org/10.1136/gut.2010.221846